Table 2 Comparison of clinical and molecular features of BRAF mutant cancers stratified by PRDM5 methylation status (n = 214)

N BRAF mutant cancers

77/214 (36.0%)

137/214 (64.0%)

Average Age

72.7

75.0

0.1

Gender (Female)

48/77 (62.3%)

91/137 (66.4%)

0.6

Location (Proximal)

62/72 (86.1%)

102/120 (84.2%)

1.0

AJCC stage I/II

36/65 (55.4%)

74/105 (70.5%)

<0.05

AJCC stage III/IV

29/65 (44.6%)

31/105 (29.5%)

Mucinous

9/34 (26.5%)

28/62 (45.2%)

0.08

Differentiation (poor)

15/34 (44.1%)

23/62 (37.1%)

0.5

MSI High

37/77 (48.1%)

83/137 (60.6%)

0.09

CIMP High

59/73 (80.8%)

95/132 (72.0%)

0.2

p53 Mutation

13/39 (33.3%)

15/68 (22.1%)

0.3

Nuclear Beta-Catenin

16/33 (48.5%)

20/59 (33.9%)

0.2